Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All-Reference-Cited by-同舟云学术

Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All

Published:2021-02-11 Issue:6 Volume:27 Page:e70-e70
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Dalal Rahul S¹^ORCID,Allegretti Jessica R¹^ORCID

Affiliation:

1. Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/27/6/e70/37946362/izab019.pdf

Reference6 articles.

1. Real-world effectiveness of ustekinumab dose intensification in Crohn’s disease;Srinivasan;Inflamm Bowel Dis.,2021

2. Predictors of ustekinumab failure in Crohn’s disease after dose intensification;Dalal;Inflamm Bowel Dis.,2020

3. Effectiveness of ustekinumab dose escalation in patients with Crohn’s disease;Ollech;Clin Gastroenterol Hepatol.,2021

4. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy;Kopylov;Aliment Pharmacol Ther.,2020;52:135–142

5. Update on the natural course of fistulizing perianal Crohn’s disease in a population-based cohort;Park;Inflamm Bowel Dis.,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing;Inflammatory Bowel Diseases;2024-07-31

2. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data;Digestive and Liver Disease;2024-05

3. The selection of the initial drug in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2023-09-27

4. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease;Frontiers in Medicine;2023-07-24

5. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities;BioDrugs;2023-01